Gene therapy for eosinophilic disorders
US12226492B2 · kind B2 · utility
0Cited by
7References
20Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 28, 2018 |
| Grant date | Feb 18, 2025 |
| Priority date | — |
| Expiry date | Jun 9, 2040 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2750/14143
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Compositions and methods for eosinophilia in a mammal are provided. In one embodiment, the composition is a viral gene therapy vector, and a single dose of the vector reduces increased numbers of eosinophils in a mammal.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.